Document is current
Any future updates will be listed below
-
Authors
Li, Yongtao
Zhou, Zhicheng
Zhang, Yiqun https://orcid.org/0000-0001-5058-5623
Jia, Deyong https://orcid.org/0000-0003-2034-0363
Wang, Ding
Reiger, Mary C.
Creighton, Chad J. https://orcid.org/0000-0002-6090-703X
Nelson, Peter S. https://orcid.org/0000-0002-5451-5726
Corey, Eva https://orcid.org/0000-0002-9244-3807
Morrissey, Colm
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-22-1-0752)
Prostate Cancer Foundation (19CHAL11)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA271457)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA97186)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21CA277368)
- License Information
-
More Information
Article History
Received: 26 February 2025
Revised: 2 October 2025
Accepted: 12 November 2025
First Online: 24 November 2025
Competing interests
: PSN has received research support from Janssen and served as a pad advisor to Janssen, Bristol Myers Squibb, Pfizer for work unrelated to the present study.
